Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. more
Time Frame | ACRS | Sector | S&P500 |
---|---|---|---|
1-Week Return | -14.17% | -2.82% | 0.15% |
1-Month Return | 27.73% | -4.22% | 1.78% |
3-Month Return | 179.49% | -9.52% | 8.7% |
6-Month Return | 184.35% | -3.45% | 12.24% |
1-Year Return | 223.76% | 5.62% | 30.9% |
3-Year Return | -76.69% | 3.8% | 30.19% |
5-Year Return | 89.02% | 39.68% | 91.72% |
10-Year Return | -70.41% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 4.23M | 6.48M | 6.76M | 29.75M | 31.25M | [{"date":"2019-12-31","value":13.53,"profit":true},{"date":"2020-12-31","value":20.74,"profit":true},{"date":"2021-12-31","value":21.64,"profit":true},{"date":"2022-12-31","value":95.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 4.05M | 5.13M | 4.71M | 11.96M | 18.08M | [{"date":"2019-12-31","value":22.43,"profit":true},{"date":"2020-12-31","value":28.39,"profit":true},{"date":"2021-12-31","value":26.07,"profit":true},{"date":"2022-12-31","value":66.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 172.00K | 1.35M | 2.05M | 17.79M | 13.17M | [{"date":"2019-12-31","value":0.97,"profit":true},{"date":"2020-12-31","value":7.58,"profit":true},{"date":"2021-12-31","value":11.51,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":74.01,"profit":true}] |
Gross Margin | 4.07% | 20.81% | 30.29% | 59.80% | 42.14% | [{"date":"2019-12-31","value":6.8,"profit":true},{"date":"2020-12-31","value":34.8,"profit":true},{"date":"2021-12-31","value":50.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":70.47,"profit":true}] |
Operating Expenses | 92.73M | 52.26M | 67.43M | 102.95M | 130.80M | [{"date":"2019-12-31","value":70.89,"profit":true},{"date":"2020-12-31","value":39.96,"profit":true},{"date":"2021-12-31","value":51.56,"profit":true},{"date":"2022-12-31","value":78.71,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (111.06M) | (50.91M) | (65.38M) | (85.15M) | (97.36M) | [{"date":"2019-12-31","value":-11105800000,"profit":false},{"date":"2020-12-31","value":-5091200000,"profit":false},{"date":"2021-12-31","value":-6538400000,"profit":false},{"date":"2022-12-31","value":-8515400000,"profit":false},{"date":"2023-12-31","value":-9735700000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (113.54M) | (51.34M) | (90.86M) | (86.91M) | (88.85M) | [{"date":"2019-12-31","value":-11354200000,"profit":false},{"date":"2020-12-31","value":-5133600000,"profit":false},{"date":"2021-12-31","value":-9086500000,"profit":false},{"date":"2022-12-31","value":-8690800000,"profit":false},{"date":"2023-12-31","value":-8884800000,"profit":false}] |
Income Taxes | 29.31M | (182.00K) | 23.42M | 1.75M | (367.00K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-0.62,"profit":false},{"date":"2021-12-31","value":79.9,"profit":true},{"date":"2022-12-31","value":5.98,"profit":true},{"date":"2023-12-31","value":-1.25,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (113.54M) | (51.15M) | (90.86M) | (86.91M) | (88.48M) | [{"date":"2019-12-31","value":-11354200000,"profit":false},{"date":"2020-12-31","value":-5115400000,"profit":false},{"date":"2021-12-31","value":-9086500000,"profit":false},{"date":"2022-12-31","value":-8690800000,"profit":false},{"date":"2023-12-31","value":-8848100000,"profit":false}] |
Income From Discontinued Operations | (47.81M) | 139.00K | - | - | - | [{"date":"2019-12-31","value":-34397.12,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (142.85M) | (51.15M) | (114.28M) | (88.66M) | (88.48M) | [{"date":"2019-12-31","value":-14285000000,"profit":false},{"date":"2020-12-31","value":-5115400000,"profit":false},{"date":"2021-12-31","value":-11428100000,"profit":false},{"date":"2022-12-31","value":-8866200000,"profit":false},{"date":"2023-12-31","value":-8848100000,"profit":false}] |
EPS (Diluted) | (3.46) | (1.20) | (1.63) | (1.33) | (1.25) | [{"date":"2019-12-31","value":-346,"profit":false},{"date":"2020-12-31","value":-120,"profit":false},{"date":"2021-12-31","value":-163,"profit":false},{"date":"2022-12-31","value":-133,"profit":false},{"date":"2023-12-31","value":-125,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ACRS | |
---|---|
Cash Ratio | 6.79 |
Current Ratio | 7.03 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ACRS | |
---|---|
ROA (LTM) | -19.39% |
ROE (LTM) | -25.83% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ACRS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.29 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.71 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ACRS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9.34 |
P/B | 1.79 |
Price/FCF | 11 |
EV/R | 4.24 |
EV/Ebitda | 0.28 |
PEG | NM |
Aclaris Therapeutics Inc (ACRS) share price today is $3.27
Yes, Indians can buy shares of Aclaris Therapeutics Inc (ACRS) on Vested. To buy Aclaris Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ACRS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Aclaris Therapeutics Inc (ACRS) via the Vested app. You can start investing in Aclaris Therapeutics Inc (ACRS) with a minimum investment of $1.
You can invest in shares of Aclaris Therapeutics Inc (ACRS) via Vested in three simple steps:
The 52-week high price of Aclaris Therapeutics Inc (ACRS) is $5.17. The 52-week low price of Aclaris Therapeutics Inc (ACRS) is $0.8.
The price-to-earnings (P/E) ratio of Aclaris Therapeutics Inc (ACRS) is
The price-to-book (P/B) ratio of Aclaris Therapeutics Inc (ACRS) is 1.79
The dividend yield of Aclaris Therapeutics Inc (ACRS) is 0.00%
The market capitalization of Aclaris Therapeutics Inc (ACRS) is $279.30M
The stock symbol (or ticker) of Aclaris Therapeutics Inc is ACRS